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Methods. The target dose is 50Gy in 25 fractions for the PTVs. Only one patient was evaluated. We use a linear accelerator Siemens
Artiste, with 160 leaves MLC of 5mm width at isocenter. Patient orientation is supine and head towards gantry. The most suitable
ﬁxation is tilted plane anchored to treatment table and soft wedge under knees. XiO TPS and step & shoot segmentation were
used. For both techniques we set a single shared isocenter, so we use half ﬁelds. For (1) we arrange the following ﬁelds: 6MV
anterior and 15MV posterior with 15MV auxiliary ﬁelds for axillary PTV; for the mammary chain one 6MV anterior–posterior
ﬁeld and 3 oblique auxiliary ﬁelds of 6MV and 15MV. For the breast, we use 6MV tangential ﬁelds and 15MV auxiliary ﬁelds. For
(2) we arrange the same as in (1) for axillary PTV; for the breast, 6MV tangential ﬁelds and 15MV auxiliary ﬁelds and 3 intensity
modulated ﬁelds with tangential internal, anterior and oblique incidence angle.
Results. Improvements shifted from 37% to 34% in lung for V20, from 27% to 22% in heart for V33, and from 49Gy to 49.6Gy in
PTV for mean dose. Nevertheless, mammary chain coverage (95% isodose volume) shifted from 94% to 91%.
Discussion. With technique 2, the left lung gets less dose than with technique 1. Although (1) got better coverage, (2) achieved
better homogeneity and without hot points. It is feasible to deliver breast treatments combining IMRT and 3DRT, achieving less
dose in the lung.
http://dx.doi.org/10.1016/j.rpor.2013.03.101
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Introduction. Over the last 10 years, intra-operative radiotherapy (IORT) has been used extensively in clinical trials but has yet
to make a signiﬁcant clinical impact on current breast cancer management strategies. There are currently two devices that
ﬁt the category of electronic brachytherapy. The Axxent® Electronic Brachytherapy System (Xoft Inc., Fremont, CA) using low-
energy radiation at a high dose rate and the Zeiss Intrabeam® (Carl Zeiss Surgical Gmbh, Oberkochen, Germany) a mobile photon
radiation system that procures a miniature electron beam driven X-ray source.
Purpose. We present our experience at Hospital de La Mancha Centro with IORT in selected patients using the Zeiss INTRABEAM®
system.
Materials and methods. We have analyzed 15 patients across from May to December 2011. Depending on clinical characteristics,
two groups of patients were treated either to accelerated partial breast irradiation (APBI) or a BOOST followed by whole breast
radiation therapy (WBRT). Main inclusion criteria for APBI patients were: (a) signature of informed consent; (b) indication for
breast conservative surgery; (c) age≥60 years; (d) histology: CDI or other favourable histology; (e) unicentric and unifocal tumor;
(f) negative margins (≥2mm); (g) sentinel lymph node negative; (h) ER negative; (i) WBRT contraindicated. Patients unsuitable for
APBI were offered IORT as boost. Doses administered for APBI and BOOST were 20Gy and 10–20Gy, respectively
Results. 9 out 15 patientswere derived to APBI and 6 to Boost plusWBRT; however, surgery ﬁnally demonstrated that somepatients
did not meet criteria and ﬁnally we did 4 APBI, 10 boost +WBRT and 1 EBRT. In all cases analyzed, the most frequent toxicity
associated to the treatment was: seroma, hyperpigmentation, edema and ﬁbrosis. After a minimum follow-up of 12 months
(median 24) no local relapses were observed.
Conclusions. Although the information was based from an extremely limited source of patients we can conclude that IORT using
the Intrabeam System is a suitable treatment for early stage breast cancer in appropriately selected patients according to ASTRO
or ASTRO guidelines.
http://dx.doi.org/10.1016/j.rpor.2013.03.102
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Purpose. To evaluate feasibility, tolerability and cosmetic outcome of intraoperative radiation therapy (IORT) as an exclusive
post-surgery treatment or anticipated boost of early stage breast cancer (BC).
Patients and methods. From February 2009 to December 2012, 33 eligible patients were treated with breast-conserving surgery
followed by IORT to the reconstructed tumor bed delivered using a linear accelerator. The doses were 21 or 10Gy depends on
results of sentinel lymph nodes biopsy. The clinical stages of patients were: 29 (87.9%) Stage I (cT1cN0) and 4 (12.1%) Stage IIA
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(cT2cN0). 25 (75.8%) presented invasive ductal BC and 4 (12.1%) invasive lobular BC. 32 (97%) patients were positive estrogen
receptor status.
Results. The median age was 66.15 (range 52–85) with an average follow up of 24 months (range 2–47). The pathologic stage were
Stage I in 24 cases (72.7%) and 9 cases (27.3%) Stage II. Dose were 2100 cGy (63.6%) as exclusive treatment, Good GEC-ESTRO
candidates 90.4%, and 1000 cGy (36.4%) as complementary treatment . Electron energies ranged from 6MeV to 12MeV, most
frequently selected were 6 (72.7%). Applicator diameter used ranged from 5 to 6 cm (5 cm, 90.9%). Beveled end of 0◦, 15◦, and 30◦
were 27.3%, 33.3% and in 39.4%, respectively. We used metallic internal patient-shielding in all procedures. The time needed for
a complete healing of the wound was less than 15 days in 78.8% of the cases. Cosmetics results according to NSABP/RTOG scale,
were excellent in 4 (12.1%), good in 16 (48.5%) and fair in 6 (18.2%). We observed a liponecrosis in 7 patients (21.2%). As regards
local control, there was no local relapse. The global survival was 97%.
Conclusions. The IORT with electrons in selected patients, requiring transportation, is an attractive accelerated partial breast
irradiation technique, secure, repeatable with limited complications and good cosmetic outcomes.
http://dx.doi.org/10.1016/j.rpor.2013.03.103
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Objective. To analyze local recurrence in patients with breast cancer with positive or close margin (<2mm) treated with conser-
vative surgery plus radiation therapy at our Center.
Materials and methods. Retrospective analysis of 157/1046 patients with breast cancer stages I and II, treated with conservative
surgery plus radiation therapy from January 1993 to December 2009. Median age: 54 years (24–88). 53% of the patients (pts) were
stage I and 47% stage II. 90%were inﬁltrating ductal carcinoma. 22% of the ptswere histological grade I, 42% grade II and 22% grade
III. The most frequent molecular subtype was luminal A (51%). 108 (69%) of the pts received adjuvant chemotherapy, medium
cycle 6 (0–16), with anthracyclines (32%), and anthracycline–taxanes (17%). 80% received hormone therapy. All patients were
treated with 50 Gy radiation therapy to the whole breast in 25 fractions± regional nodes with or without a boost to the primary
tumor bed of 16–20Gy in fractions 8–10. Kaplan–Meier curves have been used for the statistical analysis of survival. Prognostic
factors such as age, tumor size, surgery, histology, grade, hormonal and chemotherapy treatment have been associated with local
failure-free survival and overall survival (Cox regression).
Results. With a median follow-up of 89 months (19–268 months) 4 patients developed local recurrence as a ﬁrst site of failure.
At 22 years the local recurrence-free survival and overall survival were 92.9% and 76.3% respectively. Of the prognostic factors
analyzed only hormonal treatment has been associated signiﬁcantly with overall survival (p=0.02).
Conclusions. In our experience the presence of a positive or closed margin (<2mm) in patients with breast cancer treated with
conservative surgery plus radiation therapy, was not associated with a high rate of local failure, and although in the presence
of positive margin a widening of this margin is recommended, radiation therapy seems to be a safe option in those patients in
which enlargement is not possible.
http://dx.doi.org/10.1016/j.rpor.2013.03.104
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Objective. We present a case of a breast cancer (BC) patient undergoing radiotherapy with an AP, when very low doses of radiation
were delivered.
Case report. A 52-year-old woman, pre-menopausal, diagnosed of left BC. She underwent MRM+ALND. Histological examination:
DIC of 3.2 cm., GIII, vascular-lymphatic invasion (+), surgical margins (−), HR (+), HER-2/neu (+), 2/12 axillar lymph nodes. Received
adjuvant CHT [ACx4 followed by Paclitaxel +Trastuzumab (×12 weeks/for 1 year of Trastuzumab)]. We scheduled adjuvant 3DRT
with 15MV photons, total dose of 50.4Gy/1.8Gy/fr, to left chest wall and ipsilateral supraclavicular nodes. When 7.2Gy were
delivered, she was admitted in ER presenting acute retrosternal chest pain, partially improved with sublingual nitroglycerin,
exacerbated with deep breathing and decubitus position. EKG showed elevation of ST from V3 to V6. With the diagnostic of
ischemic cardiopathy versus pulmonary thromboembolism, cardiac markers, angio-TAC and cardiac catheterization discarded
ischemic disease. The rest of her ER staywas asymptomatic andwasdischarged. Five days after, thepatient resumed radiotherapy.
During the treatment she had new episode of thoracic pain solved with NSAIDs and rest. The clinical picture was attributed to
radiation-induced AP. She continued with radiotherapy and NSAIDs, remaining asymptomatic until its completion.
Discussion. Less than 1% of cases of AP are chest-wall radiation involved. When presented during RT, mimic a nonspeciﬁc peri-
carditis with chest pain, fever and/or nonspeciﬁc EKG abnormalities. Its treatment is rest and NSAIDs± colchicine. Standard
